Magnesium Deficiency Diagnosis and Management

Definition and Prevalence

Serum magnesium levels <1.3 mEq/L are considered low, with normal values varying between laboratories, according to the American Heart Association 1, 2

Ventricular arrhythmias, including PVCs, VT, and torsades de pointes, may occur in patients with magnesium deficiency, as reported by the American Heart Association 1, 2
ECG abnormalities, such as prolonged PR, QRS, and QT intervals, may be present in patients with more severe magnesium deficiency, according to the American Heart Association 1, 2

Abdominal cramps and inflammatory bowel disease are associated with magnesium deficiency, with a prevalence of 13-88% in such patients, as reported by the European Society of Gastrointestinal Endoscopy 3, 4
Fatigue, bone pain, and impaired wound healing are also common manifestations of magnesium deficiency, according to the European Society of Gastrointestinal Endoscopy 3, 4

Patients with heart failure on diuretics are at high risk of magnesium deficiency, as reported by the American Heart Association 1, 2
Patients with inflammatory bowel disease are also at high risk, with a prevalence of 13-88%, according to the European Society of Gastrointestinal Endoscopy 3, 4
Patients on proton pump inhibitors are at risk of magnesium deficiency, as reported by the European Society of Clinical Nutrition 5

Serum magnesium is not an accurate measurement of total body magnesium status, with less than 1% of magnesium stores in the blood, according to the European Society of Gastrointestinal Endoscopy 3, 4
The remainder of magnesium is stored in bone, soft tissue, and muscle, making parenteral magnesium load test a more accurate diagnostic tool, as reported by the European Society of Gastrointestinal Endoscopy 3, 4

Critically ill patients have a high prevalence of hypomagnesemia, up to 60-65%, which significantly affects outcomes, as reported by the European Society of Clinical Nutrition 5

For patients with a jejunostomy, measuring 24-hour urinary magnesium loss is ideal for assessing magnesium status, as recommended by Clinical Nutrition guidelines 6
Patients with short bowel syndrome or jejunostomy are at high risk of magnesium deficiency, according to Clinical Nutrition guidelines 6
Patients with Bartter syndrome are also at risk of magnesium deficiency, as noted by Kidney International guidelines 7
Hypomagnesemia may be associated with hypocalcemia and hypokalemia, as reported by Clinical Nutrition guidelines 6

For Bartter syndrome, plasma magnesium >0.6 mmol/L appears reasonable, based on evidence from Kidney International guidelines 7
For patients with a short bowel, supplementation may be required despite normal serum magnesium concentration, as recommended by Clinical Nutrition guidelines 6

The American College of Cardiology recommends maintaining magnesium >2 mg/dL to prevent torsades de pointes and drug-induced arrhythmias in patients with cardiac arrhythmias or QT prolongation 8
Patients with prolonged QTc interval (>500 ms) receiving QT-prolonging medications should target magnesium >2 mg/dL 8
Patients with cardiac arrhythmias, particularly ventricular arrhythmias or torsades de pointes, should maintain magnesium >2 mg/dL 8

Low plasma magnesium concentrations are associated with poor prognosis in cardiac arrest patients, with an increased risk of ventricular arrhythmias 9, 10
Electrolyte abnormalities, including hypomagnesemia, are common in patients with acute kidney injury (AKI), AKI on chronic kidney disease (CKD), or CKD with kidney failure receiving kidney replacement therapy, and should be closely monitored 11

In kidney transplant recipients, magnesium levels between 1.5-1.8 mg/dL are associated with the lowest mortality risk, with both lower and higher levels showing increased mortality 11

The American Society of Transplantation recommends checking magnesium levels every 2 weeks during the first 3 months when using calcineurin inhibitors like cyclosporine or tacrolimus, to reduce the risk of ventricular arrhythmias 11
The National Kidney Foundation suggests targeting plasma magnesium >0.6 mmol/L (approximately 1.5 mg/dL) to reduce arrhythmia risk in kidney transplant recipients 11

The American Heart Association acknowledges that abnormalities in potassium and magnesium levels can cause changes on the ECG, with T wave changes from isolated hypomagnesemia not as clearly delineated as those from potassium disturbances 12, 13, 14
The American Heart Association guidelines recommend maintaining magnesium levels to prevent ECG changes, including T wave abnormalities and QT interval prolongation 12, 13

The American College of Cardiology recommends maintaining magnesium >2 mg/dL in patients with cardiac arrhythmias or QT prolongation to prevent torsades de pointes, although this specific recommendation is not directly cited, a similar recommendation is made for maintaining magnesium levels in patients with cardiac arrhythmias 12
Hypomagnesemia can cause increased risk of torsades de pointes, even when serum magnesium levels appear normal, and ventricular arrhythmias including PVCs, VT, and potentially cardiac arrest 12

Heart failure patients on diuretics should have magnesium levels monitored closely, as hypomagnesemia is associated with more frequent ventricular arrhythmias 12

For patients with ventricular arrhythmias or torsades de pointes, magnesium bolus or infusion should be administered regardless of baseline magnesium level 12
For patients with heart failure, consider magnesium supplementation if hypomagnesemia is present, as RCTs demonstrated significantly fewer PVCs after supplementation 12

Concurrent administration of high-dose magnesium with ibutilide, a Class III antiarrhythmic, has been associated with enhanced efficacy and safety in treating arrhythmias, as recommended by the American College of Cardiology, with a strength of evidence based on clinical trials 15, 16
Magnesium is used therapeutically for drug-induced torsades de pointes, with intravenous magnesium sulfate recommended even when serum magnesium is normal, according to the American Heart Association, with a high level of evidence based on clinical guidelines 17, 18